News Agency
The Times

Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation

  • Written by PR Newswire
  • The positive CHMP opinion is based on results from the Phase II PHAROS trial,[1] which demonstrated an objective response rate (ORR) of 75% in treatment-naïve patients and 46% in previously treated patients. The safety profile is consistent with that observed in the approved metastatic melanoma indication[1]
  • The European...

Read more: Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI® (encorafenib) in...

Why Businesses Rely On Accountants in Melbourne For Financial Success

Managing finances effectively is essential for individuals, business owners, investors, and growing organisations. Financial decisions influence profitability, compliance, cash flow, and long-term wealth creation, making professional financial guidance an important part of successful planning. Many individuals and businesses choose to... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion